Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 75-83

  Bournet, Barbara ^a,b   Buscail, Camille ^c   Muscari, Fabrice ^a   Cordelier, Pierre ^b   Buscail, Louis ^a,b  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

KRAS mutation; MEK inhibitors; Pancreatic ductal adenocarcinoma; Prognosis; Quantitative PCR; Solid pancreatic masses

Indexed keywords

K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ASSAY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; GENE MUTATION; GENE TARGETING; HOPE; HUMAN; KRAS MUTATION ASSAY; META ANALYSIS (TOPIC); NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PANCREATIC NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PANCREATIC NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84955574826     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.012     Document Type: Review

References (90)

1. D.P. Ryan, T.S. Hong, and N. Bardeesy Pancreatic adenocarcinoma N Engl J Med 371 2014 2140 2141
2. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, and et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
3. T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, and et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
4. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, and et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
5. M. Ducreux, V. Boige, and D. Malka Treatment of advanced pancreatic cancer Semin Oncol 34 2 Suppl. 1 2007 S25 30
6. J.B.M. Koorstra, S.R. Hustinx, G.J.A. Offerhaus, and A. Maitra Pancreatic carcinogenesis Pancreatology 8 2008 110 125
7. S.A. Hahn, and W.H. Schmiegel Recent discoveries in cancer genetics of exocrine pancreatic neoplasia Digestion 59 1998 493 501
8. Y. Delpu, N. Hanoun, H. Lulka, F. Sicard, J. Selves, L. Buscail, and et al. Genetic and epigenetic alterations in pancreatic carcinogenesis Curr Genomics 12 2011 15 24
9. F. Klemm, and J.A. Joyce Microenvironmental regulation of therapeutic response in cancer Trends Cell Biol 25 2015 198 213
10. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, D. Beare, and et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in Cancer Nucleic Acids Res 39 2011 D945 D950 [Database issue]
11. M.P. di Magliano, and C.D. Logsdon Roles for KRAS in pancreatic tumor development and progression Gastroenterology 144 2013 1220 1229
12. A.D. Cox, C.J. Der, and M.R. Philips Targeting RAS Membrane Association: back to the future for anti-RAS drug discovery? Clin Cancer Res 21 2015 1819 1827
13. S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, and et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
14. J.T. Siveke, H. Einwachter, B. Sipos, C. Lubeseder-Martellato, G. Klöppel, and R.M. Schmid Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN Cancer Cell 12 2007 266 279
15. A.J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, and et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev 17 2003 3112 3126
16. N. Bardeesy, A.J. Aguirre, G.C. Chu, K.H. Cheng, L.V. Lopez, A.F. Hezel, and et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse Proc Natl Acad Sci U S A 103 2006 5947 5952
17. K. Izeradjene, C. Combs, M. Best, A. Gopinathan, A. Wagner, W.M. Grady, and et al. Kras(G12D) and Smad4/DPC4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas Cancer Cell 11 2007 229 243
18. C. Guerra, A.J. Schuhmacher, M. Canamero, P.J. Grippo, L. Verdaguer, L. Pérez-Gallego, and et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice Cancer Cell 11 2007 291 302
19. A.V. Pinho, L. Chantrill, and I. Rooman Chronic pancreatitis: a path to pancreatic cancer Cancer Lett 345 2014 203 209
20. C.V. Rao, A. Mohammed, N.B. Janakiram, Q. Li, R.L. Ritchie, S. Lightfoot, and et al. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice Neoplasia 14 2012 778 787
21. M.A. Pysz, S.B. Machtaler, E.S. Seeley, J.J. Lee, T.A. Brentnall, J. Rosenberg, and et al. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection Radiology 274 2015 790 799
22. A. Neesse, K.K. Frese, D.S. Chan, T.E. Bapiro, W.J. Howat, F.M. Richards, and et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice Gut 63 2014 974 983
23. B. Alagesan, G. Contino, A.R. Guimaraes, R.B. Corcoran, V. Deshpande, G.R. Wojtkiewicz, and et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer Clin Cancer Res 21 2015 396 404
24. L. Ligat, N. Saint-Laurent, A. El-Mrani, V. Gigoux, T. Al Saati, R. Tomasini, and et al. Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models Br J Cancer 2015 Oct 29 [in press]
25. A. Russo, V. Bazan, V. Agnese, V. Rodolico, and N. Gebbia Prognostic and predictive factors in colorectal cancers: Kirsten ras in CRC (RASCAL) and TP53CRC collaborative studies Ann Oncol 16 Suppl. 4 2005 44 49
26. A. Lièvre, J.B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, and et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379
27. A. Lièvre, J.B. Bachet, D. Le Corre, V. Boige, B. Landi, J.F. Emile, and et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
28. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, R.S. Herbst, and et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
29. N. Guibert, M. Ilie, E. Long, V. Hofman, L. Bouhlel, P. Brest, and et al. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives Curr Mol Med 2015 [in press]
30. M. Cserepes, G. Ostoros, Z. Lohinai, E. Raso, T. Barbai, J. Timar, and et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy Eur J Cancer 50 2014 1819 1828
31. L. Buscail, P. Faure, B. Bournet, J. Selves, and J. Escourrou Interventional endoscopic ultrasound in pancreatic diseases Pancreatology 6 2006 7 16
32. T.J. Savides, M. Donohue, G. Hunt, M. Al-Haddad, H. Aslanian, T. Ben Menachem, and et al. EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement Gastrointest Endosc 66 2007 277 282
33. S. Yoshinaga, H. Suzuki, I. Oda, and Y. Saito Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses Dig Endosc 23 Suppl. 1 2011 29 33
34. B. Bournet, A. Souque, P. Senesse, E. Assenat, M. Barthet, N. Lesavre, and et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis Endoscopy 41 2009 552 557
35. B. Bournet, J. Selves, D. Grand, M. Danjoux, N. Hanoun, P. Cordelier, and et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer J Clin Gastroenterol 49 2015 50 56
36. K.J. Livak Allelic discrimination using fluorogenic probes and 5' nuclease assay Genet Anal 14 1999 143 149
37. V. Kotoula, E. Charalambous, B. Biesmans, A. Malousi, E. Vrettou, G. Fountzilas, and et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics PLoS One 4 2009 e7746
38. A. Didelot, D. Le Corre, A. Luscan, A. Cazes, K. Pallier, J.F. Emile, and et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples Exp Mol Pathol 92 2012 275 280
39. L. Fuccio, C. Hassan, L. Laterza, L. Correale, N. Pagano, P. Bocus, and et al. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies Gastrointest Endosc 78 2013 596 608
40. M. Tada, Y. Komatsu, T. Kawabe, N. Sasahira, H. Isayama, N. Toda, and et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor Am J Gastroenterol 97 2002 2263 2270
41. M. Pellisé, A. Castells, A. Ginès, M. Solé, J. Mora, S. Castellví-Bel, and et al. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy Aliment Pharmacol Ther 17 2003 1299 1307
42. K. Takahashi, K. Yamao, K. Okubo, A. Sawaki, N. Mizuno, R. Ashida, and et al. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA Gastrointest Endosc 61 2005 76 79
43. F. Maluf-Filho, A. Kumar, R. Gerhardt, M. Kubrusly, P. Sakai, F. Hondo, and et al. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass J Clin Gastroenterol 41 2007 906 910
44. S. Reicher, F.Z. Boyar, M. Albitar, V. Sulcova, S. Agersborg, V. Nga, and et al. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses Pancreas 40 2011 1057 1062
45. T. Ogura, K. Yamao, A. Sawaki, N. Mizuno, K. Hara, S. Hijioka, and et al. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses Gastrointest Endosc 75 2012 769 774
46. M.M. Ginestà, J. Mora, R. Mayor, A. Farré, M.A. Peinado, J. Busquets, and et al. Genetic and epigenetic markers in the evaluation of pancreatic masses J Clin Pathol 66 2013 192 197
47. H. Matsubayashi Role of K-ras mutation analysis in EUS-FNA samples obtained from pancreatic solid mass J Clin Gastroenterol 49 2015 173
48. A. Khalid, J. Dewitt, N.P. Ohori, J.H. Chen, K.E. Fasanella, M. Sanders, and et al. EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer Pancreatology 11 2011 482 486
49. A.R. Thierry, F. Mouliere, S. El Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, and et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat Med 20 2014 430 435
50. H. Kinugasa, K. Nouso, K. Miyahara, Y. Morimoto, C. Dohi, K. Tsutsumi, and et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer Cancer 2015 [in press]
51. B. Kulemann, M.B. Pitman, A.S. Liss, N. Valsangkar, C. Fernández-Del Castillo, K.D. Lillemoe, and et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer Pancreas 44 2015 547 550
52. A. Kawesha, P. Ghaneh, A. Andrén-Sandberg, D. Ograed, R. Skar, S. Dawiskiba, and et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma Int J Cancer 89 2000 469 474
53. J. Lee, K.T. Jang, C.S. Ki, T. Lim, Y.S. Park, H.Y. Lim, and et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma Cancer 109 2007 1561 1568
54. J. Franko, A.M. Krasinskas, M.N. Nikiforova, N.O. Zarnescu, K.K. Lee, S.J. Hughes, and et al. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma J Gastrointest Surg 12 2008 1664 1673
55. C. Salek, L. Benesova, M. Zavoral, V. Nosek, L. Kasperova, M. Ryska, and et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer World J Gastroenterol 13 2007 3714 3720
56. H. Chen, H. Tu, Z.Q. Meng, Z. Chen, P. Wang, and L.M. Liu K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer Eur J Surg Oncol 36 2010 657 662
57. S.T. Kim, H. Lim do, K.T. Jang, T. Lim, J. Lee, Y.L. Choi, and et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy Mol Cancer Ther 10 2011 1993 1999
58. M. Oliveira-Cunha, K.D. Hadfield, A.K. Siriwardena, and W. Newman EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer Pancreas 41 2012 428 434
59. N.A. Schultz, A. Roslind, I.J. Christensen, T. Horn, E. Høgdall, L.N. Pedersen, and et al. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas Pancreas 41 2012 759 766
60. S. Boeck, A. Jung, R.P. Laubender, J. Neumann, R. Egg, C. Goritschan, and et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer J Gastroenterol 48 2013 544 548
61. B. Bournet, F. Muscari, R. Guimbaud, P. Cordelier, and L. Buscail KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer Pancreas 42 2013 543 544
62. S.H. Shin, S.C. Kim, S.M. Hong, Y.H. Kim, K.B. Song, K.M. Park, and et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival Pancreas 42 2013 216 222
63. T. Ogura, K. Yamao, K. Hara, N. Mizuno, S. Hijioka, H. Imaoka, and et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer J Gastroenterol 48 2013 640 646
64. B.V. Sinn, J.K. Striefler, M.A. Rudl, A. Lehmann, M. Bahra, C. Denkert, and et al. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma Pancreas 43 2014 578 583
65. N.T. Ihle, L.A. Byers, E.S. Kim, P. Saintigny, J.J. Lee, G.R. Blumenschein, and et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome J Natl Cancer Inst 104 2012 228 239
66. A.K. Witkiewicz, E.A. McMillan, U. Balaji, G. Baek, W.C. Lin, J. Mansour, and et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets Nat Commun 6 2015 6744
67. J.B. Bachet, R. Maréchal, P. Demetter, F. Bonnetain, J. Cros, M. Svrcek, and et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma Eur J Cancer 49 2013 2643 2653
68. M. Gayral, S. Jo, N. Hanoun, A. Vignolle-Vidoni, H. Lulka, Y. Delpu, and et al. MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer World J Gastroenterol 20 2014 11199 11209
69. F. Kullmann, A. Hartmann, R. Stöhr, H. Messmann, M.M. Dollinger, J. Trojan, and et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy Oncology 81 2011 3 8
70. G.M. Heestand, and R. Kurzrock Molecular landscape of pancreatic cancer: implications for current clinical trials Oncotarget 6 2015 4553 4561
71. N. Berndt, A.D. Hamilton, and S.M. Sebti Targeting protein prenylation for cancer therapy Nat Rev Cancer 11 2011 775 791
72. E. Van Cutsem, H. van de Velde, P. Kasarek, H. Oettle, W.L. Vervenne, A. Szawlowski, and et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
73. N.E. Martin, T.B. Brunner, K.D. Kiel, T.F. DeLaney, W.F. Regine, M. Mohiuddin, and et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer Clin Cancer Res 10 2004 5447 5454
74. S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results Ann Oncol 16 2005 847 862
75. A. Toubaji, M. Achtar, M. Provenzano, V.E. Herrin, R. Behrens, M. Hamilton, and et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers Cancer Immunol Immunother 57 2008 1413 1420
76. M.L. Hartley, N.A. Bade, P.A. Prins, L. Ampie, and J.L. Marshall Pancreatic cancer, treatment options, and GI-4000 Hum Vaccin Immunother 11 2015 931 937
77. K. Kita, S. Saito, C.Y. Morioka, and A. Watanabe Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes Int J Cancer 80 1999 553 558
78. W. Yongxiang, G. Liang, and S. Qinshu Apoptosis of human pancreatic carcinoma PC-2 cells by an antisense oligonucleotide specific to point mutated K-ras Pathol Oncol Res 20 2014 81 85
79. A. Ackley, A. Lenox, K. Stapleton, S. Knowling, T. Lu, K.S. Sabir, and et al. An algorithm for generating small RNAs capable of epigenetically modulating transcriptional gene silencing and activation in human cells Mol Ther Nucleic Acids 2 2013 e104
80. S.R. Alberts, M. Schroeder, C. Erlichman, P.D. Steen, N.R. Foster, D.F. Moore Jr., and et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial J Clin Oncol 22 2004 4944 4950
81. C. Neuzillet, P. Hammel, A. Tijeras-Raballand, A. Couvelard, and E. Raymond Targeting the Ras-ERK pathway in pancreatic adenocarcinoma Cancer Metastasis Rev 32 1-2 2013 147 162
82. F. Jaschinski, T. Rothhammer, P. Jachimczak, C. Seitz, A. Schneider, and K.H. Schlingensiepen The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2 Curr Pharm Biotechnol 12 2011 2203 2213
83. A. Shodeinde, K. Ginjupalli, H.D. Lewis, and et al. STAT3 inhibition induces apoptosis in cancer cells independent of STAT1 or STAT2 J Mol Biochem 2 2013 18 26
84. G. Bodoky, C. Timcheva, D.R. Spigel, S. Riaz, and B.E. Barton A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 30 2012 1216 1223
85. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, C. Becerra, and et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 2012 773 781
86. J.R. Infante, B.G. Somer, J.O. Park, C.P. Li, M.E. Scheulen, S.M. Kasubhai, and et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Eur J Cancer 50 2014 2072 2081
87. C. Montagut, and J. Settleman Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett 283 2009 125 134
88. P.M. LoRusso, S.S. Krishnamurthi, J.J. Rinehart, L.M. Nabell, L. Malburg, P.B. Chapman, and et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 2010 1924 1937
89. Z. Zhu, H.G. Golay, and D.A. Barbie Targeting pathways downstream of KRAS in lung adenocarcinoma Pharmacogenomics 15 2014 1507 1518
90. S. Guin, and D. Theodorescu The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer Acta Pharmacol Sin 36 2015 291 297